Can changing allopregnanolone signaling affect GABA-A function and irritability?

At age 43, menstrual-cycle changes and the menopausal transition can make this neurosteroid pathway clinically relevant, but it is not a definitive explanation for any individual’s irritability or mood symptoms.

Mechanistic evidence

• Allopregnanolone is a progesterone-derived neurosteroid that positively modulates GABA-A receptors, increasing inhibitory GABAergic signaling. Consequently, reduced exposure—or, importantly, rapid rises and falls in exposure—can change GABA-A-mediated inhibition.
• Withdrawal experiments after sustained progesterone/allopregnanolone exposure show altered hippocampal GABA-A receptor subunit expression, GABA currents, inhibition, and benzodiazepine sensitivity. Effects are adaptive rather than linear: δ-containing extrasynaptic receptors, which mediate tonic inhibition, can show cycle-linked changes in expression and neurosteroid sensitivity.
• In small menstrual-cycle studies, healthy women had greater motor-cortex inhibition in the mid-luteal than mid-follicular phase; this luteal increase was absent in women with PMDD. This is consistent with altered neurosteroid-related inhibitory regulation, although it is not direct receptor measurement.

Mood and irritability relevance

• The strongest clinical relevance is in PMDD, where the prevailing model is atypical sensitivity or adaptation to normal allopregnanolone fluctuations, rather than consistently abnormal hormone concentrations.
• A randomized PMDD trial found that isoallopregnanolone (sepranolone), which counteracts allopregnanolone’s GABA-A effects, improved negative-mood and total symptom scores versus placebo. Brexanolone and zuranolone—agents acting through this neurosteroid/GABA-A pathway—also improved depression in placebo-controlled postpartum-depression trials.
• These findings support pathway involvement, but do not establish that a specific GABA-A receptor change directly causes irritability. Evidence for perimenopausal mood symptoms is particularly limited; lower cortical GABA has been reported, without direct confirmation of allopregnanolone-driven receptor plasticity.

Bottom line

• Reduced or rapidly fluctuating allopregnanolone signaling can plausibly alter GABA-A function and contribute to reproductive-context mood symptoms, including irritability; the mechanism is well grounded biologically but remains incompletely demonstrated in humans, especially during perimenopause.